Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 3/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | PSD | A5PKW4 | 2/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | XPO1 | O14980 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
| ▸ | CBLB | Q13191 | 1/20 | 0.31 |
| ▸ | CIT | O14578 | 1/20 | 0.31 |
| ▸ | RAF1 | P04049 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | UBE2M | P61081 | 1/20 | 0.31 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21093187 | 0.89 | CYP2D6 (0.50) | CYP2D6ALOX15RETCRHR1PSD | |
| SCHEMBL18556885 | 0.88 | CYP2D6 (0.49) | CYP2D6ALOX15RETCRHR1IDO1 | |
| SCHEMBL16675898 | 0.87 | NPC1 (0.39) | CYP2D6RETKDM4ETSHRSLC6A9 | |
| SCHEMBL16812137 | 0.85 | CYP2D6 (0.48) | CYP2D6ALOX15RETCRHR1XPO1 | |
| SCHEMBL16682180 | 0.83 | CYP2D6 (0.51) | CYP2D6ALOX15RAF1UBE2MDCUN1D1 | |
| SCHEMBL18556887 | 0.83 | CYP2D6 (0.48) | CYP2D6ALOX15CRHR1 | |
| SCHEMBL16682165 | 0.82 | CYP2D6 (0.46) | CYP2D6ALOX15CRHR1IDO1XPO1 | |
| SCHEMBL18556916 | 0.82 | CYP2D6 (0.46) | CYP2D6ALOX15CRHR1SLC6A9GRM4 | |
| SCHEMBL19135717 | 0.82 | CYP2D6 (0.44) | CYP2D6ALOX15CRHR1 | |
| SCHEMBL16811839 | 0.81 | CYP2D6 (0.54) | CYP2D6ALOX15RETXPO1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | ATP5F1A, ATP5F1D, ATP5F1C | CYP2D6 3177/4885ALOX15 2000/4885RET 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.